VectivBio Holding AG (VECT) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Basel, Switzerland. Der aktuelle CEO ist Luca Santarelli.
VECT hat IPO-Datum 2021-04-08, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $1.06B.
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
